Renuka Kakarala
Internal Medicine · Williamsport, PANPI 1417012030
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 88 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Novo Nordisk at 30.2% of the total. Reporting peaked in 2022 at $526 and has fallen 90.9% since, to $48 in 2024.
Across 88 payments — averaging $15.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$409
- AbbVie$134
- Biohaven Pharmaceutical Holding Company Ltd.$118
- Amarin Pharma, Inc.$68
- Pfizer$68
- Daiichi Sankyo Inc.$65
- plus $492 from 17 others
What the payments were for
- Food & beverage$1,353100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 33 | $409 |
| AbbVie | 7 | $134 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $118 |
| Amarin Pharma, Inc. | 4 | $68 |
| Pfizer | 5 | $68 |
| Daiichi Sankyo Inc. | 4 | $65 |
| AstraZeneca | 4 | $58 |
| Biohaven Pharmaceuticals, Inc. | 3 | $56 |
| Johnson & Johnson | 4 | $53 |
| Lilly USA, LLC | 3 | $42 |
| Amgen | 2 | $36 |
| Merck | 2 | $31 |
| Sanofi-aventis U.S. LLC | 1 | $28 |
| Boehringer Ingelheim | 1 | $28 |
| Bayer | 1 | $25 |
| GSK | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Novartis | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Philips North America LLC | 1 | $11 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
How this compares
$1,353 in reported general payments places this provider in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omeprazole | 18 | $123 |
| Atorvastatin Calcium | 18 | $115 |
| Levothyroxine Sodium | 13 | $99 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Williamsport
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Daniel RaderPhiladelphia$1.7M
- Mohammed KidwaiBala Cynwyd$894K
- Ronak BhimaniNorristown$623K
- David GoldmannPhiladelphia$525K
- Christopher StillDanville$442K
- Jeffrey FreidLower Gwynedd$425K
- Cheryl PegusSpring House$370K
- Eyob FeyssaPhiladelphia$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.